definiens: means the specific formulations of the Collaboration Product that have been the subject ofthe clinical trials conducted by Nastech prior to the Execution Date ( 0.25, 0.5, 0.75, 1.0, 1.25 and 1.5 mg / spray versions ), all as more particularly described in Schedule 1.2 attached hereto, as well as any other formulations of the Licensed Product which differ from the foregoing specific formulations only with respect to the quantity or concentration of active ingredient contained therein or the quantity or concentration of any of the excipients ( e.g., buffering agents, preservatives or other inactive ingredients ) contained in such specific formulations ; provided, however, that any Licensed Product which includes different excipients or active ingredients from those contained in the current formulations or which utilizes any proprietary [COMPANY] drug delivery or formulation technology that has not been applied to the Collaboration Product as of the Execution Date shall not be considered the